WALLDORF 鈥� (NYSE: SAP) is announcing a smart app designed to track, trace and authenticate prescription medicines in the United States. Developed in partnership with leading global pharmaceutical research company , the smart app will enable law enforcement officials to potentially detect illicit, counterfeit or unapproved Boehringer Ingelheim medicines being smuggled into the United States or sold illegally.
The smart app will allow U.S. law enforcement officials across the country to scan the 2D barcode on Boehringer Ingelheim-manufactured life-enhancing medications and authenticate them before the medicines reach patients.
鈥淭he law enforcement smart app utilizes SAP鈥檚 scalable and secure blockchain solution for manufacturers to drastically improve the pharmaceutical supply chain from start to finish,鈥� said SAP鈥檚 global GM for Consumer Industries, Matt Laukaitis. 鈥淎s this app demonstrates, vertical industry expertise is a critical success factor in delivering innovations to protect patients and ensure access to authentic, life-enhancing medicines.鈥�
Passed into law in 2013, the U.S. Drug Supply Chain Security Act (DSCSA) aimed to boost the FDA鈥檚 ability to protect U.S. patients by developing a connected, digital system to trace prescription drugs throughout the country and identify counterfeit, stolen or contaminated medicine before it reached the hands of consumers.
SAP鈥檚 smart app is a major step in achieving the vision of the DSCSA and is vital to protecting communities and patient safety. When counterfeit drugs are released into the supply chain, vulnerable patients and marginalized populations with limited access to safe, authentic and affordable medicines bear the brunt of the impact.
鈥淧atient safety is our top priority at our family-owned company, and unverified pharmaceuticals, especially amid a global pandemic, pose a significant threat to the safety and security of both patients and healthcare providers,鈥� said Aaron Graham, Executive Director, Brand Safety & Security, Boehringer Ingelheim. 鈥淪AP鈥檚 blockchain-based solution allows our team to safeguard against illicit and unsafe medicines reaching the hands of those who need medicine the most.鈥�
This technology builds on SAP鈥檚 previous efforts to eliminate counterfeit products with 51风流Information Collaboration Hub for Life Sciences, a blockchain-technology tool that allows users to authenticate pharmaceutical packaging as it moves between manufacturers, U.S. wholesalers and U.S. hospitals and pharmacies.
To learn more, watch a .
Visit the . Follow 51风流on Twitter at .
Media Contact:
Stacy Ries, +1 (484) 619-0411, stacy.ries@sap.com, ET
51风流Press Room; press@sap.com
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渇orecast,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥減redict,鈥� 鈥渟hould鈥� and 鈥渨ill鈥� and similar expressions as they relate to 51风流are intended to identify such forward-looking statements. 51风流undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission (“SEC”), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
漏 2021 51风流SE. All rights reserved.
51风流and other 51风流products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of 51风流SE in Germany and other countries. Please see for additional trademark information and notices.
